<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00286130</url>
  </required_header>
  <id_info>
    <org_study_id>CECOG/Core 1.2.001</org_study_id>
    <secondary_id>EUDRACT number 2004-002391-42</secondary_id>
    <nct_id>NCT00286130</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>A Randomised, Open-label Phase II Study Evaluating the Efficacy and Safety of Folfox6 + Cetuximab as First-line Therapy in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central European Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central European Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Patients with metastatic colorectal cancer the following treatments first-line
      Folfiri+Cetuximab first-line Folfox6 + Cetuximab will be concerning efficacy and safety.

      The trial compares Folfiri + Cetuximab and Folfox6 + Cetuximab concerning efficacy and safety
      as first
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The multicenter randomized phase II study will enroll a target of approximately 150
      first-line patients with metastatic CRC.

      EGFR expression is not required for study entry, however, the EGFR status will be measured
      retrospectively.

      Patients are randomized to Arm A or Arm B. Arm A: FOLFOX 6 in combination with cetuximab Arm
      B: FOLFIRI in combination with cetuximab. Both efficacy and safety data will be collected.
      The investigators will assess response to treatment at 6 weeks, 12 weeks and thereafter every
      12 weeks based on imaging Following permanent treatment cessation (stop of all study
      treatments) patients will be followed-up for.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the percentage of patients surviving without disease progression in each arm at 9 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS rates at 3,6,12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) in each arm</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFOX 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FOLFOX 6:
Oxaliplatin 100 mg/m² d1 concurrent with
Leucovorin 400 mg/m², followed by
Bolus 5FU 400 mg/m² , followed by
Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFIRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FOLFIRI:
Irinotecan 180 mg/m² day 1 concurrent with
Leucovorin 400 mg/m² followed by
Bolus 5FU 400 mg/m², followed by
Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan</intervention_name>
    <arm_group_label>FOLFOX 6</arm_group_label>
    <arm_group_label>FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX 6</intervention_name>
    <description>FOLFOX 6:
Oxaliplatin 100 mg/m² d1 concurrent with
Leucovorin 400 mg/m², followed by
Bolus 5FU 400 mg/m² , followed by
Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:</description>
    <arm_group_label>FOLFOX 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>FOLFIRI:
Irinotecan 180 mg/m² day 1 concurrent with
Leucovorin 400 mg/m² followed by
Bolus 5FU 400 mg/m², followed by
Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks</description>
    <arm_group_label>FOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of histologically confirmed adenocarcinoma of the colon or rectum

          -  Metastatic colorectal carcinoma not suitable for curative-intent resection

          -  Availability of tumor sample (or able and willing to provide tumor sample) for EGFR
             assessment

          -  Presence of at least one lesion measurable unidimensional by CT scan or MRI (Target
             lesion(s) must not lie within an irradiated area)

          -  ECOG performance status of &lt; 2 at study entry

        Exclusion Criteria:

          -  Brain metastasis (known or suspected)

          -  Previous chemotherapy for metastatic CRC or adjuvant therapy with oxaliplatin or
             irinotecan. Adjuvant therapy with 5 FU or derivatives is allowed if the chemotherapy
             treatment free interval is &gt; 6 months

          -  Surgery (excluding diagnostic biopsy) or irritation within 4 weeks prior to study
             entry

          -  Cocurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not
             indicated in the study protocol

          -  Any investigational agent(s) within 4 weeks prior to entry

          -  Previous exposure to EGFR-pathway targeting therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Werner Scheithauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep. of Internal Medicine I, Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LKH Leoben, Abt. für Innere Medizin</name>
      <address>
        <city>Leoben</city>
        <state>Steiermark</state>
        <zip>8700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Klinik für Innere Medizin I</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital &quot;Queen Joanna&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1504</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBALO National Oncology Center</name>
      <address>
        <city>Sofia</city>
        <zip>1754</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital for Tumors</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Rebro</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bank of Cyprus Oncology Center</name>
      <address>
        <city>Nikosia</city>
        <country>Cyprus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Hospital Brno, Dept. Of Clinical Oncology</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles University Prague, Dep. of Oncology</name>
      <address>
        <city>Prague</city>
        <zip>12808</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical Center</name>
      <address>
        <city>Budapest</city>
        <zip>1135</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markusovsy Hospital</name>
      <address>
        <city>Szomathely</city>
        <zip>39700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Csolnoky Ferenc County Hospital</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Souraski Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Amadora Sintra, Servico de Oncologia</name>
      <address>
        <city>Amadora</city>
        <zip>2720</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Beja</name>
      <address>
        <city>Beja</city>
        <zip>78000</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Distrital de Faro</name>
      <address>
        <city>Faro</city>
        <zip>8000-386</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Geral de Sto. António</name>
      <address>
        <city>Porto</city>
        <zip>4000-377</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Teotóno -</name>
      <address>
        <city>Viseu</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic Bucuresti</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic Cluj</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bratislava</city>
        <zip>83310</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Hacettepe University, Oncology Unit</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gazi University Medical Faculty</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9 Eyul University Medical Faculty, Dep of Oncology</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Cyprus</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2006</study_first_submitted>
  <study_first_submitted_qc>February 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2006</study_first_posted>
  <last_update_submitted>April 30, 2012</last_update_submitted>
  <last_update_submitted_qc>April 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic colorectal cancer</keyword>
  <keyword>FOLFOX 6</keyword>
  <keyword>FOLFIRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

